You are here

Democrats Demand Probe of Trump Health Nominee

It’s ‘politics as usual’ as Tom Price heads to the HHS

Senate Democrats have demanded an ethics probe into Tom Price, President-elect Donald Trump’s pick for Secretary of the Department of Health and Human Services, following a report that he traded in health care company stocks while supporting legislation in Congress that could affect those shares, according to an article posted by the Reuters news service.

Senate Democratic leader Chuck Schumer and others made the demand as Republicans forged ahead with their plan to repeal the Patient Protection and Affordable Care Act (PPACA). The Democrats called on the Office of Congressional Ethics to investigate Price’s stock trades.

“Every American should be shocked by this,” Schumer told reporters.

Phil Blando, a Trump transition spokesman, called Schumer’s demand a “stunt” to deflect attention from the PPACA’s “dismal record.”

Blando said the ethics questions Schumer raised about Price should be directed to three sitting Democratic senators, Delaware’s Tom Carper, Virginia’s Mark Warner, and Rhode Island’s Sheldon Whitehouse, “who own and have traded hundreds of thousands of dollars in pharmaceutical and health insurance company stocks.”

“Hypocrisy is apparently alive and well this morning in Washington,” Blando said.

Republicans will control the White House and Congress once Donald Trump takes office on January 20. In a series of Twitter posts, Trump has blasted the Democrats over the PPACA, taunting Schumer as “head clown.”

Source: Reuters; January 5, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs